New Decentralized Clinical Trial (DCT) Patient Satisfaction and Participation Report

800 Current and Future Clinical Trial Participants Link Satisfaction and Willingness to Participate with Decentralized Strategies - September 21, 2022 - Life Science Strategy Group, LLC

Paras Biopharmaceuticals Finland Oy Has Been Identified as One of the "Fastest Growing Companies in the Nordic Biotechnology Therapeutics & Diagnostics Industry"

Paras Biopharmaceuticals Finland Oy Has Been Identified as One of the "Fastest Growing Companies in the Nordic Biotechnology Therapeutics & Diagnostics Industry"

Paras Biopharmaceuticals is pleased to announce that the company has been identified as one of the Fastest Growing Companies in the Nordic Biotechnology Therapeutics and Diagnostics industry by Plimsoll Publishing UK. - September 01, 2022 - Paras Biopharmaceuticals Finland Oy

Creative Diagnostics Launches Custom Virus Production Service

Creative Diagnostics has recently introduced the research community with customized virus production services. - August 26, 2022 - Creative Diagnostics

Creative Diagnostics Launches New Livestock Infectious Diseases Antigens

Creative Diagnostics announced the launch of more than 20 antigens for the development of veterinary infectious diseases diagnostics and vaccines. - August 26, 2022 - Creative Diagnostics

CABRI Announces Call for Proposals on Specialized Pro-Resolving Mediator Analytical Methods

The Cayman Biomedical Research Institute (CABRI) is offering research grants in amounts up to $100,000 to support essential research on specialized pro-resolving mediator (SPM) analytical methods. - August 26, 2022 - Cayman Chemical Company

Deadline Extended: CABRI Announces Undergraduate Fellowships and Scholarship Program

The Cayman Biomedical Research Institute (CABRI) is accepting applications from undergraduate students who have been offered an unpaid laboratory research position under an accredited principal investigator. Applications will be accepted from August 22 until September 18, 2022. - August 26, 2022 - Cayman Chemical Company

Pharma CI Conference Returns Next Month: Meet Hundreds of Industry Leaders at the Top Event for 15+ Years

Pharma CI Conference Returns Next Month: Meet Hundreds of Industry Leaders at the Top Event for 15+ Years

Ready, set, engage! The Pharma CI USA Conference & Exhibition is back in person and ready to deliver the industry-leading experience that has made Pharma CI the gold standard event for more than fifteen years. The much-anticipated return happens this September 21-22 at the Newark Liberty... - August 18, 2022 - Pharma CI Conference

Peptineo, LLC Selected by EPA to Provide EPA Nationwide Coverage for Point of Care (POC) COVID-19 Testing

The Environmental Protection Agency (EPA), Cincinnati Acquisition Division (CAD), has awarded Peptineo LLC, an emerging aerospace, health services, and defense solutions company, a three-year Blanket Purchase Agreement (BPA) to support a comprehensive COVID-19 testing program in support of the... - August 07, 2022 - Peptineo

Creative Diagnostics Launches Monkeypox Virus Antibodies and Antigens to Support MPXV Research

Creative Diagnostics announced the launch of several Monkeypox Virus Antibodies and Antigens for the detection of Monkeypox viruses. - July 22, 2022 - Creative Diagnostics

Creative Diagnostics Introduces New Cell-Based ELISA Services

Creative Diagnostics is offering comprehensive services for Cell-based ELISA that can measure the reduction of viral antigens in infected cells using anti-virus antibodies or compounds. - July 22, 2022 - Creative Diagnostics

Creative Diagnostics Introduces CC50/IC50 Assay Services for Pharmaceutical Safety

Creative Diagnostics introduced CC50/IC50 testing services with a high level of detection sensitivity and accuracy. - June 11, 2022 - Creative Diagnostics

Creative Diagnostics Launches Measles Virus Antigens for the Detection of Antibodies

Creative Diagnostics announced the release of new measles virus antigens suitable for both IgM and IgG detection. - June 11, 2022 - Creative Diagnostics

Creative Diagnostics Launches Antibody-Dependent Enhancement Assay Services

Creative Diagnostics recently introduces comprehensive services for antibody-dependent enhancement (ADE) assay. - May 26, 2022 - Creative Diagnostics

Creative Diagnostics Announces Antigens for Epstein-Barr Virus Antibody Tests

Creative Diagnostics recently launched recombinant antigens p18 and p23 (viral capsid antigens, VCA), p54 and p138 (early antigens, EA) and EBNA1 (nuclear antigen, EBNA). - May 26, 2022 - Creative Diagnostics

Molekule Consulting Announces the Launch of E.U. - Based Operations

Molekule Consulting Announces the Launch of E.U. - Based Operations

Molekule Consulting announces the launch of an E.U. - based business / Molekule Hub continuing their focus on the development of global strategy and advisory services for the biopharmaceutical sector. - May 24, 2022 - Molekule Consulting

NuvOx Pharma Announces Issuance of a New Patent

NuvOx Pharma has been issued US Patent No. 11,304,899, entitled “Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof.” - May 19, 2022 - NuvOx Pharma

NuvOx Appoints Dr. Robert King to SAB

NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, appointed Dr. Robert King to its Scientific Advisory Board (SAB). Dr. King is a seasoned life science executive with over 30 years’... - May 11, 2022 - NuvOx Pharma

Creative Diagnostics Introduces New Nipah Virus Antigens and Antibodies

Creative Diagnostics recently launches a series of NiV recombinant antigen and antibody pairs. - April 30, 2022 - Creative Diagnostics

Microvascular Therapeutics Finalizes Facility Certification for the Production of Its Product, MVT-100

Microvascular Therapeutics (MVT), a clinical stage biotechnology company, finalized its manufacturing facility certifications for the GMP production of its first product, MVT-100. - April 21, 2022 - Microvascular Therapeutics, Inc.

NuvOx Technology Featured in Prominent Peer Review Journal

NuvOx Pharma’s technology, which is developed as a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, was featured in the prominent journal of Frontiers of Neurology. - April 19, 2022 - NuvOx Pharma

NuvOx Finalizes Facility Certification, Poising for Phase IIb Trials

NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, finalized its manufacturing facility certifications for Phase IIb trials. - April 17, 2022 - NuvOx Pharma

Dr. Claudia C. Cotca of C3 Think Tank Appointed as Advisor Chair of Advanced Technology Academic Research Center (ATARC) on Digital AI & Data Analytics Warfighter Health

Dr. Claudia C. Cotca of C3 Think Tank appointed as Advisor Chair of Advanced Technology Academic Research Center (ATARC) on Digital AI & Data Analytics Warfighter Health. Together with leadership and military health experts, stakeholders and program officers, Dr. Claudia C Cotca will help support and contribute to the scope and mission of ATARC’s Warfighter Health in incorporating responsibly artificial intelligence in military medicine. - April 13, 2022 - C3 Think Tank

Microvascular Therapeutics Receives Funds from Commercialization Readiness Program for the Development of Its Ultrasound Contrast Agent, MVT-100

MicrovMicrovascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Commercialization Readiness Program grant from the National Institute of Heart, Lung, and Blood Institute (NHLBI). Wyatt Unger, MD, MBA, Chief Medical Officer of MVT said, “We are... - April 09, 2022 - Microvascular Therapeutics, Inc.

Creative Diagnostics Launches Staphylococcal Enterotoxin Antigens

Creative Diagnostics recently launches a range of natural and recombinant staphylococcal enterotoxin antigens. - March 31, 2022 - Creative Diagnostics

NuvOx Receives Notice from the Breakthrough DOD Award for Its Immuno-Oncology Program

On February 11th, 2022, NuvOx Pharma received notice from the Department of Defense (DOD) office of the Congressionally Directed Medical Research Programs (CDMRP) that the Company has been awarded a grant from the Breast Cancer Research Program Breakthrough Award. The grant would fund a... - March 05, 2022 - NuvOx Pharma

Timothy Healey Joins the Board of Director at Microvascular Therapeutics

Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Timothy Healey to the MVT Board of Directors. Mr. Healey bring a global perspective to pharmaceutical launch and commercialization. “I am very pleased and honored... - February 23, 2022 - Microvascular Therapeutics, Inc.

NuvOx to Participate in the BIO CEO Investor Conference

NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, will participate in BIO CEO & Investor Conference, held at New York City from February 14 - 17, 2022. The management team will be... - February 11, 2022 - NuvOx Pharma

ImaRx Investments Receives ISO-7 Certification for Its GMP Manufacturing Suite: Both Microvascular Therapeutics and NuvOx Pharma Will Benefit

ImaRx Investments, LLC, an investment firm based in Tucson, Arizona, has received ISO-7 certification on February 1st for its GMP manufacturing suite. The 1,800 square foot, ISO-5 capable clean room is designed for manufacturing injectable drugs. The facility is the only one of its kind in Southern... - February 08, 2022 - Microvascular Therapeutics, Inc.

Shiv Kapoor Joins the Board of Directors at Microvascular Therapeutics

Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Shiv Kapoor to the MVT Board of Directors. Mr. Kapoor will bring extensive experience in corporate strategy and financing from both biotechnology and finance... - February 03, 2022 - Microvascular Therapeutics, Inc.

NuvOx to Present at Various Bio Forums in JPM Week

NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, will participate in various Bio forums held Jan 10 – 14, 2022. Dr. Evan Unger, NuvOx’s Chief Executive Officer, is presenting in... - January 14, 2022 - NuvOx Pharma

Global Regenerative Academy Announces Prof. Tahsin Beyzadeoglu as President

Global Regenerative Academy Announces Prof. Tahsin Beyzadeoglu as President

Global Regenerative Academy, independent subsidiary of the Global Regenerative Group Inc., has new board leadership. GRA President is now Prof. Tahsin Beyzadeoglu as announced during the opening Ceremony of GRC Dubai 2021 (November 19-21, 2021) by Mr. Mihail Blagoev (GRG Inc. VP) after being elected by the Scientific Board. - December 21, 2021 - Global Regenerative Group

Mirror Biologics, Inc. Announces Close of a $14 Million Financing Round

Mirror Biologics, Inc. Announces Close of a $14 Million Financing Round

This Funding will be Used, in Part, to Launch an Asian Phase II/III Randomized Controlled Registration Trial for Advanced Liver Cancer in Q1/2-2022. - December 09, 2021 - Mirror Biologics, Inc.

Parvus Therapeutics Announces Development and Manufacturing Agreement with Resilience to Advance Novel Autoimmune Drug Candidate PVT201

Parvus Therapeutics, a biopharmaceutical company developing Navacim™ platform-based disease-specific immunoregulator therapeutics to treat autoimmune diseases by activating endogenous generation of disease-specific regulatory T cells (Tregs) without impairing normal immune system function,... - November 29, 2021 - Parvus Therapeutics U.S., Inc.

Parvus Therapeutics and Ardena Enter Agreement for Tech Transfer, Scale-Up and GMP Manufacturing of Navacim Nanoparticles

Today Parvus announced it has entered into an agreement with Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO), for process development, scale-up and GMP manufacturing of NavacimTM nanoparticles, a key building block for all of our Navacim platform drug development candidates. - November 19, 2021 - Parvus Therapeutics U.S., Inc.

CANNA/Hemp Extraction Labs USA Announces Joint Venture Partnerships for Cannabis Cultivators/Growers and Cannapreneurs

CANNA/Hemp Extraction Labs USA (CHELUSA) announced today they are offering to finance and commission Cannabis Extraction Labs and Cannabis Cloning Labs in NM, NJ, AZ, IL, MT and VA. CHELUSA is looking to form strategic partnerships with Cultivators/Growers and Cannapreneurs in these key states. The... - November 18, 2021 - Hemp Extraction Labs USA

Mirror Biologics Announces Issuance of US Patent Covering Next Generation Therapeutic Vaccine Technology for Treatment of Cancer and Infectious Disease

Mirror Biologics Announces Issuance of US Patent Covering Next Generation Therapeutic Vaccine Technology for Treatment of Cancer and Infectious Disease

Mirror Biologics, Inc., a private clinical stage biopharmaceutical company, today announces the issuance of US Patent No. 11,160,852, “Method of Vaccinating Using Allogeneic Cells,” covering methods for creating a next generation of therapeutic vaccines against cancers and infectious... - November 17, 2021 - Mirror Biologics, Inc.

Pascal Biosciences Announces Financing

Pascal Biosciences Inc. (“Pascal” or the “Company”) (TSXV: PAS) (OTC: PSCBF) (FSE: 6PB-FF) is pleased to announce a non-brokered private placement financing of up to 9,000,000 units (each a “Unit”) of securities at a price of $0.10 per Unit for aggregate gross proceeds of up to $900,000.00 (the “Offering”). - October 29, 2021 - Pascal Biosciences

OmeCare and Hillsborough City School District Renew Partnership for Student and Faculty COVID-19 PCR Testing

Partnership helps district ensure safety standards and meet COVID-19 testing protocols for the 2021-2022 school year. - October 16, 2021 - OmeCare

NuvOx Pharma Receives Phase I STTR Grant from NINDS for Preclinical Studies in Stroke

NuvOx Pharma, a Tucson based biotechnology company, has received a $478,000 NIH Phase I Small Business Technology Transfer (STTR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) under award number R41NS124450. STTR programs are highly competitive programs that... - October 12, 2021 - NuvOx Pharma

OmeCare and LifeSite Announce COVID-19 Testing Solution Partnership

The partnership provides a turnkey approach for workplaces, schools, major conventions and other group events looking to ensure safety and meet governmental mandates for students, staff, employees and event participants. - October 01, 2021 - OmeCare

Cayman Chemical Receives Grant to Evaluate Use of KMN-159 to Accelerate Dental Implant Osseointegration

The National Institute of Dental and Craniofacial Research has awarded Cayman Chemical with a $1,700,500 grant to explore Cayman’s patented small molecule bone repair agent KMN-159 as the active pharmaceutical ingredient (API) in a drug-device combination to improve the mechanical anchorage... - September 19, 2021 - Cayman Chemical Company

AdvantaPure(R) Announces Fall Trade Show Appearances - Includes Events in the Northeast U.S.

AdvantaPure, the high purity division of NewAge Industries, will exhibit its silicone and TPE tubing and molded assemblies at the ISPE Boston Show, BioProcess International 2021, and Interphex, all taking place in September and October. AdvantaPure will also highlight its recent clean room expansion and its in-process building renovation at the events. The company is increasing its tubing manufacturing capacity to help meet demand for its Single-Use products. - September 16, 2021 - AdvantaPure

Mirror Biologics, Inc. Announces Initial Clearance for Phase II/III Clinical Trial (ALIVE) in Advanced Liver Cancer

Mirror Biologics, Inc. Announces Initial Clearance for Phase II/III Clinical Trial (ALIVE) in Advanced Liver Cancer

Mirror Biologics, Inc, (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ vaccine immunotherapy for cancer and infectious diseases where... - September 10, 2021 - Mirror Biologics, Inc.

NuvOx Pharma Generates Positive Preclinical Data Showing NanO2TM Boosts the Efficacy of Immunotherapy in a Mouse Model of Triple Negative Breast Cancer

NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has generated positive preclinical data showing that its lead drug, NanO2TM, boosts the efficacy of immunotherapy in a mouse model of triple negative breast cancer. Triple negative breast cancer (TNBC) is a particularly deadly form of... - September 09, 2021 - NuvOx Pharma

Foxx Life Sciences Celebrates Major Expansion

Foxx Life Sciences celebrates two new manufacturing facilities in Londonderry, New Hampshire and Hyderabad, India. The new locations add four additional SUT (Single Use Technologies) Cleanrooms that will allow Foxx to meet the high demands of their biotechnology and biopharmaceutical customers. New... - August 04, 2021 - Foxx Life Sciences

NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM in Ischemic Stroke

NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO2TM, in ischemic stroke. Stroke affects nearly 800,000 patients each year in the US. It is the fourth leading cause of death in this... - July 29, 2021 - NuvOx Pharma

NuvOx Pharma Announces Issuance of New Patent Covering a New Method of Treating Cancer Utilizing Lead Drug Candidate NanO2TM

NuvOx Pharma, a privately-held clinical-stage biotechnology company based in Tucson, Arizona, has further expanded its patent portfolio in oxygen therapeutics with the issuance of US Patent No. 10946097, “Fractionated radiotherapy and chemotherapy with an oxygen therapeutic,” describing... - July 23, 2021 - NuvOx Pharma

Microvascular Therapeutics Has Received Funds from the National Heart, Lung and Blood Institute (NHLBI)

Microvascular Therapeutics (MVT) has received funds from the from the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health for its program to treat cardiovascular disease, which kills more Americans than any other disease. As a leader in fluorocarbon... - July 19, 2021 - Microvascular Therapeutics, Inc.

Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase I/II Universal Viral Vaccine Clinical Trial (ALLOPRIME) in Healthy Adults Over 65 Years Old

Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase I/II Universal Viral Vaccine Clinical Trial (ALLOPRIME) in Healthy Adults Over 65 Years Old

Mirror Biologics, Inc, (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ vaccines for cancer and infectious diseases where the active... - July 14, 2021 - Mirror Biologics, Inc.

Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase IIB Clinical Trial (STIMVAX) in Patients with Metastatic Colorectal Cancer

Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase IIB Clinical Trial (STIMVAX) in Patients with Metastatic Colorectal Cancer

Mirror Biologics, Inc. (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ cancer vaccines in which the active ingredients are living... - July 09, 2021 - Mirror Biologics, Inc.

Press Releases 101 - 150 of 1,340